Arterial ischemic stroke occurs as a result of abnormal clinical circumstances that alter hemostasis and cause thrombosis, either within a vessel or as an embolic event. Understanding normal hemostasis, including differences between children (developmental hemostasis) and adults, will provide background for determining the pathophysiology of stroke and potential treatments.
Normal Hemostasis
Hemostasis is maintained through vessel wall blood composition and flow. Advances in our understanding of the physiology of hemostasis have often resulted from the study of mouse models. 1 The endothelium of the vessel wall plays a major role in ensuring patency of vasculature by secreting 3 thromboregulating substances. Nitrous oxide 2, 3 and prostacyclin 4 inhibit platelet adherence, and ectonucleotidase CD39 degrades adenosine triphosphate directly into adenosine monophosphate, bypassing adenosine diphosphate production; thus, adenosine diphosphate-induced aggregation via P2Y1 receptor is inhibited. 5 Vessel wall damage can occur as a result of disruption or more subtle endothelial cell alterations as hypothesized by Sacco et al, 1 resulting in activation of hemostasis. When vessel wall damage occurs, platelet activation occurs via 2 separate pathways. One pathway is invoked by collagen, whereas the other is invoked by tissue factor. Either or both pathways can predominate depending on the type of vasculature damage or disease entity. 6, 7 Exposed collagen in the subendothelial matrix interacts with platelets, resulting in adhesion by 2 mechanisms: by binding to von Willebrand factor followed by platelet glycoprotein 1b-IX-V and through direct interaction with platelet glycoprotein VI. 8 Shear force influences which receptor plays the foremost role in platelet tethering to the vessel wall, but glycoprotein VI and glycoprotein 1 b are essential for platelet adhesion. 6, 9, 10 The integrin a 2 b 1 also plays a lesser role in platelet adhesion. 11, 12 Tissue factor in microparticles 13, 14 circulates in its inactive form 15, 16 and requires activation, which has been hypothesized to occur through protein disulfide isomerase released by activated endothelial cells and platelets. 1, 14 Transformed tissue factor causes activation of factor VII and factor IX. The combination of activated factor X and factor VIII, known as the tenase complex, causes activation of factor X. Activated factor X then combines with factor V to form the prothrombinase complex, which in turn activates a small amount of prothrombin to thrombin. The minute amount of thrombin generated is a catalyst that activates factors V and VIII to their most active cofactor forms, factor VIIIa and factor Va. Large amounts of thrombin are then generated as a result of the continued action of the tenase and prothrombinase complexes ( Figure 1) . 17 Thrombin activates fibrinogen to form nonpolymerized thrombus but also activates platelets (Figure 2) 18 through cleaving protease activating receptor 1, causing platelet granule release (adenosine diphosphate stored in the dense granules, and serotonin and thromboxane A 2 stored in the a granules) and further platelet activation. Adenosine diphosphate activates platelets through receptors P2Y1 and P2Y12 (Figure 2 ). Serotonin activates platelets through 5 hydroxytryptamine 2A receptors (Figure 2 ). Thromboxane A 2 activates platelets through the thromboxane receptor ( Figure 2) .
In addition to activating tissue factor, protein disulfide isomerase activates glycoprotein IIb/IIIa (a IIb b 3 ) on platelets, which binds to the ligands fibrinogen and von Willebrand factor, thus promoting platelet recruitment to the thrombus and platelet-platelet interactions. [19] [20] [21] Increased affinity for the ligands occurs when platelets bound to the damaged vessel wall are activated and glycoprotein IIb/IIIa undergoes a transformational change. 22 Blood flow shear rates determine the binding ligand, with low and high shear rates binding with fibrinogen and von Willebrand factor, respectively. 8 Microparticles circulate in the blood and carry proteins associated with the cell type they were derived from (eg, leukocytes, platelets, endothelial cells, smooth muscle cells, and monocytes). Activated platelets expose the protein P selectin 23 on their surface that binds to circulating microparticles derived from monocytes that have the counter receptor displayed, P selectin glycoprotein ligand 1 (PSGL-1). 13 Through this mechanism, tissue factor exposed on these microparticles 13, 14 is responsible for further thrombin generation and thrombus extension.
Developmental Hemostasis
Compared with adults, children have decreased physiologic levels of proteins involved in hemostasis (factors XII, XI, X, IX, VII, II), fibrinolysis (plasminogen and tissue plasminogen activator), and inhibition of hemostasis (antithrombin, proteins C and S) and fibrinolysis (plasminogen activator inhibitor-1). As a result of these differences, known as developmental hemostasis, 24, 25 children generate less thrombin than adults when hemostasis is activated. 26 As a result, idiopathic thrombosis is rare in children; however, thrombosis does occur and 
Challenges With Pediatric Arterial Ischemic Stroke
The cause of childhood arterial ischemic stroke is not completely understood and appears to be multifactorial. Consequently, studies evaluating specific therapeutic agents become challenging. The ideal therapeutic agent should inhibit thrombus formation/extension without causing hemorrhage while maintaining hemostasis. Current agents have a single mode of action, either inhibiting platelet activity or hemostasis or actively promoting clot degradation (fibrinolysis). These therapeutic approaches are too primitive for the complexity of modulating hemostatic balance.
Multiple receptors participate in platelet activation; thus, single-target therapeutic agents may not protect against all mechanisms of platelet activation. Furthermore, anticoagulation prevents thrombus formation or extension, which is associated with increased risk for hemorrhage and can have devastating consequences in children with arterial ischemic stroke. In addition, few pharmacokinetic and pharmacodynamic studies using current therapeutic agents have been performed in children to determine and guide dosing and duration of therapy. 
Conclusions
Further elucidation of the mechanisms of pediatric arterial ischemic stroke is necessary to provide guidance to determine the most effective therapeutic agents and dosing regimens, followed by the establishment of safety and efficacy profiles.
